Boston Medical Sciences
Developing AIM4CRC, an AI-powered virtual colonoscopy system for laxative-free colorectal cancer screening.
Website: https://b-ms.tech/
Cover Block
From the public record
| Field | Value |
|---|---|
| Name | Boston Medical Sciences |
| Tagline | Developing AIM4CRC, an AI-powered virtual colonoscopy system for laxative-free colorectal cancer screening. |
| Headquarters | Tokyo, Japan [Boston Medical Sciences株式会社] |
| Founded | 2023 [NEDO, October 2026] |
| Stage | Series B [PR TIMES, November 2026] |
| Business Model | SaaS |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | East Asia |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Founder | Masaki Okamoto [NEDO, October 2026] |
| Funding Label | Series B |
| Total Disclosed Funding | $37,600,000 [PR TIMES, November 2026] |
Links
From the public record
- Website: https://b-ms.tech/
- Careers: https://b-ms.tech/en/career/
The Short Version
PUBLIC Boston Medical Sciences is developing AIM4CRC, a software-as-a-medical-device system for laxative-free CT colonography, and it merits investor attention now because the company has paired a sizable late-2026 financing with a clearly defined regulatory and clinical development agenda in Japan and the United States [PR TIMES, November 2026] [NEDO, October 2026]. The company was founded in 2023 in Tokyo by Masaki Okamoto, who is identified as founder and CEO across NEDO, LinkedIn, and company-linked materials, although the broader founding story remains only partially documented in public sources [NEDO, October 2026] [LinkedIn, 2026] [Crunchbase].
AIM4CRC’s differentiation, based on the evidence available, is its effort to combine deep learning-based virtual bowel cleansing with automatic polyp detection from colon CT images captured without laxative intake, a workflow that could improve patient acceptance if clinical performance and regulatory clearance follow [NEDO, October 2026] [FIRST CVC] [JIC Venture Growth Investments, February 2025]. The technical promise is directionally compelling, but investors should keep the claim set narrow: public materials establish the product concept and intended use, not broad commercial deployment or outcomes data [NEDO, October 2026] [Boston Medical Sciences株式会社].
On team quality, the strongest verified fact is Okamoto’s role as founder and chief executive; some company-adjacent sources also describe physician-research links to Harvard Medical School and Massachusetts General Hospital, but those details are less consistently corroborated and should be treated with care [LinkedIn, 2026] [NEDO, October 2026] [CB Insights, October 2024]. On capitalization, the public record points to a Series B round of ¥5.55 billion, reported at roughly $37.6 million, announced in November 2026 with participation from Japan Growth Capital Investment Corporation, Global Brain, Beyond Next Ventures, and Nomura SPARX-related entities, giving the company a meaningful balance sheet for R&D, regulatory work, and overseas expansion [PR TIMES, November 2026] [Nomura Holdings, November 2026].
Over the next 12 to 18 months, the key public milestones to watch are regulatory progress, evidence of clinical implementation, and any proof that the company can move from investor and government validation to named healthcare customers or institutional deployments [Boston Medical Sciences株式会社] [PR TIMES, November 2026] [NEDO, October 2026].
Single-source, plausible -- Core company, founder, product, and financing facts are supported by NEDO, PR TIMES, Nomura, LinkedIn, and Crunchbase, but several team-background and product-positioning details remain only partially corroborated.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series B |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | East Asia |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Total disclosed approximately $37.6M |
The Company in Brief
PUBLIC
Boston Medical Sciences presents as an early-stage Tokyo medical software company built around a single, clinically specific thesis: make CT-based colorectal screening easier for patients by removing the laxative-preparation step from the workflow [Boston Medical Sciences株式会社]. The company website describes AIM4CRC as an AI-powered virtual colonoscopy system for colorectal cancer screening, and Crunchbase lists Boston Medical Sciences as a Tokyo-based company founded in 2023 [Boston Medical Sciences株式会社] [Crunchbase].
The public chronology is still short, but it is becoming easier to trace. Crunchbase identifies Masaki Okamoto as the founder, while the company website positions Boston Medical Sciences as the developer of AIM4CRC and presents recruiting activity through its careers page, which suggests the business is moving beyond pure research positioning into company-building mode [Crunchbase] [Boston Medical Sciences株式会社]. The available company and Crunchbase materials do not add much legal-entity detail beyond the operating name and headquarters, so the cleanest read is that this remains a focused, product-led company centered on one software-as-a-medical-device program [Boston Medical Sciences株式会社] [Crunchbase].
Single-source, plausible -- Confirmed by company website and Crunchbase, with limited legal-entity detail in the cited public record.
What They Have Built
Mixed sourcing
The product story is narrower than the financing headlines, which is usually where diligence should start. Boston Medical Sciences says it is developing AIM4CRC, a software as a medical device for CT colonography that applies deep learning to two specific steps in the workflow: virtual bowel cleansing and automatic polyp detection on colon CT images [NEDO, October 2026]. FIRST CVC describes the same core functionality in similar terms, adding that the system is designed for scans captured without laxative intake, which is central to the company’s clinical claim rather than a minor usability feature [FIRST CVC].
Public descriptions consistently frame AIM4CRC around reducing the preparation burden that limits screening uptake. NEDO characterizes the program as a non-invasive colorectal cancer screening system based on deep learning, while JIC Venture Growth Investments says the company is aiming for clinical implementation of a non-laxative virtual colonoscopy system originating from Japan [NEDO, October 2026] [JIC Venture Growth Investments, February 2025]. The company has also stated that AIM4CRC was accepted into the U.S. Food and Drug Administration Total Product Life Cycle Advisory Program, which matters because it suggests an active regulatory engagement path, although TAP admission is not a clearance or approval decision [Boston Medical Sciences, 2026].
What remains less developed in public materials is everything around the model edge cases and workflow integration. The available sources do not verify sensitivity, specificity, reader time reduction, hospital deployment status, or how AIM4CRC fits into radiology reporting systems, so the current evidence supports the product concept and regulatory intent more clearly than clinical performance in practice [NEDO, October 2026] [Boston Medical Sciences株式会社].
Single-source, plausible -- Core product functions are corroborated by NEDO and FIRST CVC, but performance and deployment details are limited and partly company-sourced.
Market Size and Demand
PUBLIC
This market matters now because Boston Medical Sciences is aiming at a part of screening that still loses patients before the scan begins: bowel preparation remains a practical deterrent, while regulators and health systems continue to look for higher-throughput, earlier cancer detection pathways [NEDO, October 2026] [Maiko M. - Product Marketing Manager - Mizuho America, Inc., 2026].
The evidence base here is narrower than investors would usually want for a clean TAM build. No named third-party market report for cathartic-free CT colonography, virtual bowel cleansing, or AI polyp-detection software appears in the supplied public record, so the market has to be framed through the adjacent categories the company itself is clearly entering: colorectal cancer screening, CT colonography workflow software, and software as a medical device for radiology [NEDO, October 2026] [FIRST CVC]. Public sources do support the product premise that AIM4CRC is being developed as SaMD for colon CT images, with deep learning used for virtual bowel cleansing and automatic polyp detection [NEDO, October 2026] [FIRST CVC]. That makes the practical serviceable market less about all cancer diagnostics and more about imaging centers, hospitals, and screening programs willing to add or expand CT-based colorectal screening if prep burden falls.
Demand drivers are visible even without a formal sizing report. The company and its backers repeatedly position the product around reducing or removing laxative preparation, and that framing is consistent across NEDO, investor materials, and company statements rather than confined to a single marketing page [NEDO, October 2026] [JIC Venture Growth Investments, February 2025] [Boston Medical Sciences株式会社]. If that claim holds up clinically and in workflow economics, the tailwind is straightforward: a screening modality that is easier for patients to tolerate can enlarge the addressable screened population, particularly among people who defer conventional prep-heavy pathways. The caveat is equally plain. Public materials establish intent and technical direction, not reimbursement adoption, guideline inclusion, or hospital purchasing behavior.
The nearest adjacent and substitute markets are more legible than the core niche. On one side sit incumbent colorectal screening pathways, including optical colonoscopy and conventional CT colonography with cathartic prep. On the other sit broader AI-imaging categories where software is sold into radiology departments as a clinical workflow or detection layer. BMS's public financing narrative suggests management sees the opportunity as crossing both lines: first as a differentiated imaging workflow product, then as a screening-access product if regulators and providers accept the cathartic-free approach [PR TIMES, November 2026] [Nomura Holdings, November 2026]. That is strategically sensible, but it also means adoption depends on two validations at once, technical performance and care-pathway acceptance.
Regulatory and macro forces matter more here than in a typical enterprise software market. The company says AIM4CRC has been accepted into the U.S. Food and Drug Administration's Total Product Life Cycle Advisory Program, which, if borne out in subsequent FDA disclosures, would suggest an effort to move early on evidence generation and commercialization planning in the United States [Boston Medical Sciences, 2026]. Public statements also say proceeds from the November 2026 financing are intended for Japanese and U.S. regulatory work, domestic commercialization, and overseas expansion, particularly in the U.S. market [PR TIMES, November 2026] [Nomura Holdings, November 2026]. For investors, that frames the addressable market as regulation-gated rather than sales-led in the near term. The market can be large in principle, but the investable question is when software clearance, clinical validation, and site-level workflow fit convert that theoretical demand into budgeted purchases.
| Market lens | What public sources support | Source quality |
|---|---|---|
| Core niche | AI software for laxative-free CT colonography with virtual bowel cleansing and polyp detection | Supported by government and investor materials [NEDO, October 2026] [FIRST CVC] |
| Immediate buyers | Hospitals, imaging centers, and screening programs are the implied users, but no named customers or contracts are disclosed | Inferred from product use case and regulatory positioning [NEDO, October 2026] [PR TIMES, November 2026] |
| Adjacent markets | Broader radiology SaMD and colorectal screening workflows | Supported indirectly by product description and commercialization plan [NEDO, October 2026] [Nomura Holdings, November 2026] |
| Expansion path | Japan first, with stated U.S. regulatory and overseas ambitions | Supported by financing announcement and company materials [PR TIMES, November 2026] [Boston Medical Sciences, 2026] |
The table underscores the central point: the opportunity is credible as an adjacent radiology-SaMD entry, but public evidence is still too thin to defend a precise market-size model for the cathartic-free screening niche itself. That keeps this section analytical rather than numeric.
Single-source, plausible -- Built primarily from NEDO, PR TIMES, Nomura Holdings, and company materials; market framing is directionally supported, but no independent third-party sizing report for the exact niche was identified.
Who Else Is Fighting for This
Market structure
MIXED Boston Medical Sciences appears to be competing less against a single named startup peer than against the existing colorectal-screening stack, where optical colonoscopy is the clinical default, CT colonography is an established but narrower modality, and the company is trying to widen CT colonography adoption by removing laxative preparation with software [NEDO, October 2026] [Boston Medical Sciences株式会社] [JIC Venture Growth Investments, February 2025].
The first layer of competition is incumbent procedure volume. Standard colonoscopy remains the reference pathway for direct visualization and intervention, which means any software-only CT workflow still has to prove it can pull screening demand toward a radiology-led modality rather than simply improve a niche existing option. Public materials for Boston Medical Sciences describe AIM4CRC as software that performs virtual bowel cleansing and automatic polyp detection on colon CT images, not as a replacement for therapeutic colonoscopy, and that distinction matters commercially as much as clinically [NEDO, October 2026] [FIRST CVC].
The second layer is the CT colonography ecosystem itself. Boston Medical Sciences is positioning AIM4CRC as a software-as-a-medical-device product that could make CT colonography more tolerable by removing laxative intake from the exam workflow, which is a meaningful wedge if patient preparation is the main point of friction [PR TIMES, November 2026] [Maiko M. - Product Marketing Manager - Mizuho America, Inc., 2026]. But the available public record does not name hospital customers, imaging-center deployments, or channel partners, so the present competitive map is clearer on product intent than on commercial foothold [CB Insights, February 2025] [Boston Medical Sciences株式会社].
A third layer comes from adjacent substitutes rather than direct lookalikes. Stool-based screening, conventional CT colonography workflows, and standard colonoscopy all sit in the same clinical decision set even if they use different economics and care settings. On the evidence available, Boston Medical Sciences is best understood as a workflow challenger inside imaging-based colorectal screening, not yet as the owner of the broader screening pathway [NEDO, October 2026] [PR TIMES, November 2026].
Edge and durability
MIXED The company’s clearest edge today is regulatory and clinical positioning around a very specific claim: virtual bowel cleansing plus AI-based polyp detection for colon CT images acquired without laxative intake [NEDO, October 2026] [FIRST CVC].
That matters because narrow scope can be an advantage in medical software. Boston Medical Sciences has tied the product to a defined screening friction point, and outside validators have echoed that framing, including NEDO and investor communications that describe the system as a non-laxative or cathartic-free virtual colonoscopy approach [NEDO, October 2026] [Nomura Holdings, November 2026] [JIC Venture Growth Investments, February 2025]. The FDA Total Product Life Cycle Advisory Program entry, cited by the company, also suggests the team is trying to convert a technical claim into a regulated product path rather than remain at the prototype stage [Boston Medical Sciences, 2026].
The durability of that edge is less settled. If the moat rests on proprietary training data, reader-performance gains, or integration into radiology workflows, the public evidence does not yet show it. The financing record is material, with a disclosed ¥5.55 billion Series B in November 2026 and prior reported fundraising, which should support R&D and regulatory work, but capital alone is not a lasting shield if larger imaging or medtech players decide the category is attractive [PR TIMES, November 2026] [Tracxn] [NEDO, October 2026]. In other words, the current edge looks regulatory and problem-specific, durable if approvals and adoption compound, perishable if the underlying capability is reproducible.
Exposure points
MIXED The company is most exposed where the public record is thinnest: distribution, installed-base access, and proof that laxative-free CT colonography changes purchasing behavior rather than simply improving product narrative [Boston Medical Sciences株式会社] [CB Insights, February 2025].
Even so, the practical competitive pressure is easy to identify by category. Endoscopy incumbents own physician habits and the therapeutic pathway, while established imaging vendors and radiology software companies, whether or not they are direct entrants today, would likely hold stronger relationships with health systems if they chose to pursue similar bowel-cleansing or CAD-style features. Boston Medical Sciences also does not appear, from the cited public sources, to own a proprietary care channel such as a screening network, payer pathway, or hospital group rollout [NEDO, October 2026] [PR TIMES, November 2026].
That leaves the company dependent on evidence generation and regulation doing the heavy lifting. If AIM4CRC secures differentiated clinical validation and clearance ahead of broader entrants, that dependence can turn into an asset. If not, the product risks being evaluated as one feature in a larger imaging stack, where smaller standalone vendors usually have less pricing power and less control over procurement timing [Nomura Holdings, November 2026] [Boston Medical Sciences株式会社].
Eighteen-month scenario
MIXED The most plausible near-term competitive outcome is a market shaped by execution milestones rather than winner-take-all displacement.
Winner if X: Boston Medical Sciences is the most plausible near-term winner if it converts its current financing and FDA TAP participation into visible regulatory progress and early clinical implementation in Japan, because the public story is already aligned around a specific patient-experience benefit and a defined SaMD use case [PR TIMES, November 2026] [Boston Medical Sciences, 2026] [NEDO, October 2026]. Loser if Y: Boston Medical Sciences is also the most plausible near-term loser if clinical adoption stalls and the company cannot show that radiology buyers value laxative-free workflow enough to change practice, since the fallback options are already entrenched and do not require providers to underwrite a new software category [CB Insights, February 2025] [Boston Medical Sciences株式会社].
A more measured reading is that the next 18 months will likely decide whether AIM4CRC becomes a category-defining screening application or remains an interesting technical layer inside a conservative care pathway. With no named public startup rivals in the current source set, the real contest is between a new workflow and existing clinical behavior.
Single-source, plausible -- Core product positioning is corroborated by NEDO, PR TIMES, Nomura, and company materials, but named competitor evidence is absent and several competitive inferences rely on category structure rather than directly confirmed head-to-head reporting.
Opportunity
PUBLIC The prize here is not incremental imaging software, it is the chance to become a clinically trusted screening layer for colorectal cancer that lowers one of the main friction points in CT colonography, laxative preparation, and then carries that position into regulated markets in Japan and the United States [NEDO, October 2026] [PR TIMES, November 2026].
The clearest upside case is that Boston Medical Sciences becomes the reference software for cathartic-free CT colonography in markets where screening uptake is constrained by patient burden and clinical workflow friction. That outcome is still early, but it is not purely aspirational on the public record. NEDO describes AIM4CRC as a medical device software program using deep learning for virtual colon cleansing and automatic polyp detection on colon CT images, which establishes a specific product scope rather than a broad AI claim [NEDO, October 2026]. The company also disclosed a ¥5.55 billion Series B in November 2026, with proceeds earmarked for R&D, clinical development, regulatory work in Japan and the U.S., domestic commercialization, and overseas expansion, particularly in the U.S., which suggests management is financing a defined regulatory and go-to-market path rather than an open-ended research effort [PR TIMES, November 2026].
The range of plausible scale outcomes depends less on raw software demand than on whether BMS can turn a clinically differentiated workflow into a standard-of-care adjunct. Public evidence supports three possible routes.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Win the regulatory wedge | AIM4CRC secures the approvals and clinical validation needed to become a recognized SaMD option for laxative-free CT colonography in Japan first, then selectively in the U.S. | Progress through Japanese regulatory work and U.S. FDA engagement, including the disclosed TAP Pilot Program participation [Boston Medical Sciences, 2026] | The company has already said it is pursuing regulatory work in both countries, and public funding announcements tie fresh capital directly to those milestones [PR TIMES, November 2026] [NEDO, October 2026] |
| Become the imaging workflow default | Hospitals and imaging centers adopt AIM4CRC as an add-on to CT colonography workflows because it reduces preparation burden while preserving a software-first deployment model | Early clinical implementation in Japan and evidence that cathartic-free exams improve patient acceptance [JIC Venture Growth Investments, February 2025] [FIRST CVC] | Multiple public sources describe the same core product function, virtual bowel cleansing plus automated polyp detection, which is a sharper workflow wedge than general-purpose radiology AI [NEDO, October 2026] [FIRST CVC] |
| Build a cross-border screening platform | BMS uses Japan as the first commercialization base, then expands into the U.S. with a regulatory-first strategy and investor backing suited to international scale | Execution against the Series B use of proceeds for overseas business development, especially in the United States [PR TIMES, November 2026] | The investor group in the November 2026 round includes Japan Growth Capital Investment Corporation, Global Brain, Beyond Next Ventures, and Nomura SPARX participation, which provides both financing depth and a signal that the company has support for a longer commercialization arc [PR TIMES, November 2026] [Nomura Holdings, November 2026] |
The compounding mechanism, if it appears, would likely come from regulatory credibility, clinical data accumulation, and workflow embedding rather than a consumer network effect. Each additional clinical implementation could improve the company’s evidence base for safety and utility, strengthen relationships with imaging sites, and make it easier to justify reimbursement or procurement conversations for the next account. Public sources do not yet show named customers or deployment scale, so this flywheel is still conditional, but two early ingredients are visible: a narrowly defined SaMD product with a concrete clinical job to do, and enough capital to pursue the expensive sequence of validation, approval, and market entry across two major jurisdictions [NEDO, October 2026] [PR TIMES, November 2026].
The size of the win is best framed through category position rather than current metrics, because no confirmed revenue or deployment data is public. If BMS were to become a standard software layer for cathartic-free colorectal screening across meaningful portions of Japan and selected U.S. provider networks, the asset could plausibly resemble a strategic imaging-AI platform rather than a single-feature tool. There is no reliable public comparable in the supplied materials with a cited market cap or acquisition multiple, so a precise valuation anchor would overstate confidence. Even so, a successful cross-border, regulated screening platform with differentiated clinical workflow ownership could support venture-scale outcomes in medical imaging software, potentially into the high hundreds of millions of dollars in enterprise value (scenario, not a forecast), provided the company converts its current regulatory and financing momentum into actual adoption [PR TIMES, November 2026] [Nomura Holdings, November 2026].
Single-source, plausible -- This section relies mainly on NEDO, PR TIMES, Nomura Holdings, and company-linked program disclosures. The core product and financing facts are corroborated, but commercial traction and valuation comparables are not publicly established.
Sources
From the public record
[Boston Medical Sciences株式会社] Boston Medical Sciences株式会社 | https://b-ms.tech/
[NEDO, October 2026] Boston Medical Sciences, Inc. | NEDO | https://www.nedo.go.jp/english/activities/startups/company10.html
[PR TIMES, November 2026] Boston Medical Sciences, Series B Round Raises ¥5.55 Billion in Equity | https://prtimes.jp/main/html/rd/p/000000012.000129637.html
[LinkedIn, 2026] Masaki Okamoto - Astellas Pharma | LinkedIn | https://www.linkedin.com/in/okamotomasaki/
[Crunchbase] Boston Medical Sciences - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/boston-medical-sciences
[Nomura Holdings, November 2026] Nomura SPARX Invests in Boston Medical Sciences | https://www.nomuraholdings.com/en/news/nr/nspi20261113a.html
[CB Insights, October 2024] Meiji Yasuda Life Insurance Company | https://www.cbinsights.com/investor/meiji-yasuda-life-insurance-company
[CB Insights, February 2025] Boston Medical Sciences | https://www.cbinsights.com/company/boston-medical-sciences
[Tracxn] Boston Medical Sciences - 2026 Funding Rounds & List of Investors - Tracxn | https://tracxn.com/d/companies/boston-medical-sciences/__pAqC02DpR2iR24HT17dU5nJk-hU_C4ngIVvAgoKYgYc/funding-and-investors
Articles about Boston Medical Sciences
- Boston Medical Sciences Is Betting $37.6 Million on a Laxative-Free Colonoscopy — The startup's AIM4CRC system uses AI to digitally cleanse CT scans, aiming to improve screening rates by removing a major patient barrier.